Medicenna Therapeutics Corp. (MDNA.TO)
CAD 1.75
(-2.23%)
CAD 1.75
(-2.23%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -25.46 Million CAD | -1746.15% |
| 2022 | 1.54 Million CAD | 106.83% |
| 2021 | -22.64 Million CAD | -31.79% |
| 2020 | -17.18 Million CAD | -106.79% |
| 2019 | -8.3 Million CAD | -76.49% |
| 2018 | -4.7 Million CAD | 36.94% |
| 2017 | -7.46 Million CAD | 2.17% |
| 2016 | -7.63 Million CAD | -472.03% |
| 2015 | -1.33 Million CAD | -60.06% |
| 2014 | -833.49 Thousand CAD | -8.84% |
| 2013 | -765.77 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.63 Million CAD | 73.84% |
| 2023 FY | -25.46 Million CAD | -1746.15% |
| 2023 Q3 | -4.97 Million CAD | -33.68% |
| 2023 Q1 | -2.86 Million CAD | 25.78% |
| 2023 Q2 | -3.72 Million CAD | -30.08% |
| 2023 Q4 | -13.9 Million CAD | -179.37% |
| 2022 Q2 | -896 Thousand CAD | 78.44% |
| 2022 Q4 | -3.85 Million CAD | -237.95% |
| 2022 Q3 | -1.14 Million CAD | -27.34% |
| 2022 Q1 | -4.15 Million CAD | -29.6% |
| 2022 FY | 1.54 Million CAD | 106.83% |
| 2021 Q4 | -3.2 Million CAD | 33.31% |
| 2021 FY | -22.64 Million CAD | -31.79% |
| 2021 Q1 | -6.38 Million CAD | -9.84% |
| 2021 Q2 | -8.17 Million CAD | -28.06% |
| 2021 Q3 | -4.8 Million CAD | 41.22% |
| 2020 Q1 | -2.35 Million CAD | 12.54% |
| 2020 FY | -17.18 Million CAD | -106.79% |
| 2020 Q2 | -3.78 Million CAD | -60.99% |
| 2020 Q4 | -5.81 Million CAD | -8.92% |
| 2020 Q3 | -5.33 Million CAD | -40.99% |
| 2019 Q4 | -2.68 Million CAD | -12.52% |
| 2019 Q3 | -2.38 Million CAD | -25.48% |
| 2019 Q2 | -1.9 Million CAD | -47.09% |
| 2019 Q1 | -1.29 Million CAD | -23.41% |
| 2019 FY | -8.3 Million CAD | -76.49% |
| 2018 FY | -4.7 Million CAD | 36.94% |
| 2018 Q4 | -1.04 Million CAD | 39.12% |
| 2018 Q3 | -1.72 Million CAD | -91.95% |
| 2018 Q2 | -897.65 Thousand CAD | 13.54% |
| 2018 Q1 | -1.03 Million CAD | 20.78% |
| 2017 Q1 | -2.25 Million CAD | 48.21% |
| 2017 Q4 | -1.31 Million CAD | 39.91% |
| 2017 FY | -7.46 Million CAD | 2.17% |
| 2017 Q2 | -1.71 Million CAD | 23.83% |
| 2017 Q3 | -2.18 Million CAD | -26.93% |
| 2016 Q1 | -10.65 Thousand CAD | 31.48% |
| 2016 FY | -7.63 Million CAD | -472.03% |
| 2016 Q3 | -2.17 Million CAD | -12788.71% |
| 2016 Q4 | -4.35 Million CAD | -99.9% |
| 2016 Q2 | -16.9 Thousand CAD | -58.64% |
| 2015 Q2 | -157.11 Thousand CAD | -964.29% |
| 2015 Q4 | -15.55 Thousand CAD | 97.25% |
| 2015 Q3 | -566.33 Thousand CAD | -260.47% |
| 2015 FY | -1.33 Million CAD | -60.06% |
| 2015 Q1 | -14.76 Thousand CAD | 0.0% |
| 2014 FY | -833.49 Thousand CAD | -8.84% |
| 2013 FY | -765.77 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -3.78 Million CAD | -573.542% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 31.894% |
| Helix BioPharma Corp. | -9.26 Million CAD | -174.892% |
| Microbix Biosystems Inc. | -39.48 Thousand CAD | -64398.645% |
| Satellos Bioscience Inc. | -15.88 Million CAD | -60.274% |
| Oncolytics Biotech Inc. | -27.75 Million CAD | 8.237% |
| Sernova Corp. | -38.99 Million CAD | 34.698% |